Halda Therapeutics
Scott Phillips has a strong background in finance and executive leadership. Scott is currently serving as the Chief Financial Officer at Halda Therapeutics, where they were a founding executive. Scott successfully raised $76 million in equity financing and negotiated a multi-million dollar venture debt facility. Scott is responsible for overseeing G&A functions and is a member of the IP strategy team.
Prior to this role, Scott was the Chief Financial Officer at Normunity, a biotech company specializing in IO antibodies. Scott played a crucial role in raising $65 million in Series A financing and led all G&A functions. Scott also negotiated key agreements with manufacturing partners and Alloy Therapeutics for antibody development.
Scott has extensive consulting experience as a CFO, working with companies such as Amylyx Pharmaceuticals, Bioasis Technologies, and Allovir. Scott has supported early-stage organizations in financial strategy, commercial strategy, and accounting. Scott also provided assistance in capital raise preparation and S-1 readiness.
Before their consulting work, Scott served as the Senior Vice President of Finance at Biohaven Pharmaceuticals, where they created accounting and finance processes for the company. Scott established deliverables for the Audit Committee and implemented plans to achieve Sarbanes-Oxley 404 compliance.
Scott's earlier experience includes senior leadership positions at Alexion Pharmaceuticals, where they established and led various finance functions. Scott was responsible for global business finance, strategic finance, financial planning and analysis, and global finance business partnerships.
Scott began their career at PricewaterhouseCoopers as a Senior Manager, working on diverse projects in the technology industry group. Scott provided expertise in SEC reporting matters and technical issues impacting technology companies.
Prior to joining PricewaterhouseCoopers, Scott worked as a Senior Accountant at Ernst & Young.
Overall, Scott Phillips has a comprehensive work history in finance and executive roles, with a focus on fundraising, G&A functions, strategic planning, and SEC reporting.
Scott Phillips completed their high school education at Brookfield High School from 1991 to 1994. Scott then went on to pursue a bachelor's degree in Accounting at UNC Kenan-Flagler Business School from 1996 to 1999. Additionally, Scott earned a Master of Accounting (MAC) degree during their time at UNC Kenan-Flagler Business School.
Halda Therapeutics
1 followers
Halda is inventing novel precision medicines for oncology. Specifically, we are developing RIPTAC™ therapeutics, a new drug modality for the treatment of cancer. Founded by world renowned Yale scientist, Professor Craig Crews, Halda invented RIPTAC therapeutics as an innovative cancer treatment approach that does not rely on traditional oncogenic disease drivers to target cancer. This powerful technology is designed to overcome the known bypass mechanisms of drug resistance, a common limitation of today’s precision cancer medicines. Using a novel ‘hold and kill’ mechanism, RIPTAC therapeutics target cancer cells selectively by bringing two proteins together in a tightly regulated manner, causing the loss of an essential function for cell survival and subsequent cancer cell death. We have built a pipeline of RIPTAC therapeutics for major cancer types, uniquely addressing the unmet needs of drug resistant cancer patients, and we will continue to invent new medicines using our proprietary platform technology. We are a bold company where collaboration, passion, and creativity thrive, all of which allows us to push the boundaries of drug discovery to identify better solutions. Halda is proud to be a New Haven, CT based biotech, located with headquarters and state-of-the-art labs in Science Park.